The future has arrived #CUBETechFair

CUBE10 - 12 May 2017, Berlin, Germany.
Startups are setting up, speakers are tweaking their talks, and CUBE Tech Fair is ready for you... The inaugural CUBE Tech Fair kicks off tomorrow, and what a show they have for you. CUBE Tech Fair has brought the Crème de la Crème of the tech world to Berlin.

Over 300 startups from our ecosystem will be exhibiting, in addition to pitching for a €1 million prize in CUBE Challenge. The final round will be judged by Apple Co-Founder, Steve Wozniak.

Let's welcome keynote speeches by:

  • Pablos Holman (Founder of Intellectual Ventures Laboratory, notorious hacker)
  • Michael Müller (Mayor of Berlin)
  • Steve Wozniak (Co-Founder of Apple),
  • Robin Wright (Award-winning actress, tech activist),
  • Brigitte Zypries (Federal Minister of Economic Affairs and Energy)

The fireside chats, keynotes speeches, and panel discussions will deep-dive into specific industry areas. Topics include:

  • Infrastructure & Interconnectivity
  • Digital Health & Life Sciences
  • Machinery & Manufacturing
  • Cybersecurity & Hacking
  • Climate Change & Smart Energy Systems
  • Blockchain Innovations and more!

The Welcome Reception has filled up fast, and organisers already have exceptional guests including top startups, corporates and investors - and for good reason. Come, network and enjoy food tech at it's best - CUBE will be serving up bites from the incredible German Michelin-starred chef Christian Lohse. And on top of that all the ingredients are being provided by anti-food-waste startup SirPlus.

Don't have a booked seat? No problem! The event is still open to all Tech Fair badge holders!

On Thursday night, organisers take to the CityCube's terrace for the official Tech Fair party - they will of course be bringing Berlin's party spirit to the tech world.

Still don't have a ticket?! Get one now!

World Pharma News readers can benefit from an exclusive discount - get 30% off the ticket price using our unique promo code worldpharmanewsCUBE17 when you register online here.

About CUBE
CUBE is a Berlin-based global innovation ecosystem that aims to promote, create and foster partnerships between industry players and startups in life sciences & digital health, machinery & manufacturing as well as infrastructure & connectivity. Being part of the CUBE ecosystem allows all participants to collaborate on innovative products and ideas in response to concrete industry needs.

The annual CUBE Tech Fair, our flagship event, will take place for the first time in May 2017. For further information, please visit http://tech-fair.cube-global.com.

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...